Galapagos NV

Galapagos NV is a fully integrated biotechnology company headquartered in Mechelen, Belgium, dedicated to transforming patient outcomes through life-changing science and innovation in immunology and oncology. Founded in 1999 as a joint venture between Crucell and Tibotec, it has evolved from genomics research to developing novel therapies using small molecules, biologicals, and advanced cell therapies. The company leverages deep disease expertise and multiple drug modalities, including a groundbreaking decentralized, point-of-care CAR-T manufacturing platform acquired through CellPoint and AboundBio in 2022, enabling rapid vein-to-vein production in about seven days. Key programs include the CAR-T candidate GLPG5101 for relapsed/refractory non-Hodgkin lymphoma and the TYK2 inhibitor GLPG3667 in Phase 2 for autoimmune diseases like systemic lupus erythematosus. Previously, it commercialized Jyseleca for rheumatoid arthritis and ulcerative colitis before transferring that business to Alfasigma in 2024. With over 1,200 employees across two continents and partnerships like Gilead and Thermo Fisher Scientific, Galapagos focuses on high unmet medical needs, accelerating a diversified pipeline from discovery to commercialization to deliver more years of life and quality of life for patients worldwide.